Women With Type 2 Diabetes Who Receive Long-Acting Insulin Glargine May Have Increased Risk Of Breast Cancer,

reports that researchers found that “women with type 2 diabetes who received long-acting insulin glargine...had a 1.4-fold increased risk of breast cancer compared with women who were given intermediate-acting neutral protamine Hagedorn (NPH) insulin during roughly 4 years and up to 12 years of follow-up.” However, individuals “who received insulin detemir...did not have any increased risk of breast cancer.” Medscape adds that “of note, the breast-cancer signal with insulin glargine was only significant among prior insulin users and not new users.” https://login.medscape.com/login/sso/getlogin?urlCache=aHR0cHM6Ly93d3cubWVkc2NhcGUuY29tL3ZpZXdhcnRpY2xlLzg4NzIwNA==&ac=401